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Abstract
Despite the well-documented improved survival of coronary heart disease with the use of statins, their effects
on atherosclerotic plaques are not yet fully understood. While some studies suggest statins may reduce plaque
volume, the reduction is small even with the use of high-dose statins. Due to this small change in plaque
volume, other effects of statin therapy on plaques have been proposed. A large meta-analysis by Banach et al.
explored statin effects on plaque composition detected by intravascular ultrasound (IVUS). We discuss the
mechanisms of plaque composition modification demonstrated in their study and its implications on
atherosclerotic plaque stabilization.
Please see related article: http://www.biomedcentral.com/1741-7015/13/229.
Background
Since the landmark publication of the 4S trial, which dem-
onstrated improved survival with the use of statins [1], a
series of studies have consistently documented a clear
reduction of cardiovascular events with statin treatment
in different settings. The benefit is clearly associated with
important low-density lipoprotein (LDL) cholesterol re-
duction achieved by this class of drugs; however, their
effects on atherosclerotic plaques have not yet been fully
elucidated.
Initial magnetic resonance imaging (MRI) studies of
the aorta suggested that statin use might result in ath-
erosclerotic plaque regression as early as 6 months after
initiation of therapy [2]. These findings were further
corroborated by initial data using intravascular ultra-
sound (IVUS) evaluation of individuals treated with
very high-dose statins [3]. The potential regression or
reversion of the atherosclerotic process brought significant
excitement in the cardiovascular community. Many
understood that changes to the atherosclerotic plaque
burden could better summarize the whole statin effect on
atherosclerosis beyond LDL cholesterol reduction itself,
although such changes in plaque volume were limited to
1 % reduction of the plaque burden. Based on the poten-
tial advantages of this strategy some authors even sug-
gested that plaque regression should be considered a new
target for therapy [4].
Some of this excitement slowly faded away due to two
important pieces of evidence. First, the association be-
tween plaque burden and incident cardiovascular events
did not prove to be true for other classes of drugs. For
example, while niacin effectively reduced the carotid
intima-media thickness (IMT), a surrogate marker of ath-
erosclerosis [5], this was not translated in any clinical
benefit on a larger trial [6]. In contrast, while ezetimibe
failed to reduce the carotid IMT in the same study [5], its
use resulted in a significant reduction of cardiovascular
events beyond baseline statin treatment [7]. Second, while
even lower statin doses result in additional reduction in
the rate of cardiovascular events, the regression of plaque
volume with statins was limited only to subgroups treated
with higher doses and longer duration [8].
New insights on the effects of statins on atherosclerotic
plaques
A new meta-analysis by Banach et al. [9] reinvestigated
the effect of statins on atherosclerosis progression and
was recently published in BMC Medicine. The authors
included nine studies with more than 830 individuals in
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whom virtual histology data was available. This study
supported previous findings that higher statin doses result
in significant plaque volume reduction, while lower statin
doses does not. More interestingly, the pooled virtual hist-
ology data demonstrated that this small change in plaque
volume is a poor summary of plaque composition change.
On the one hand, the fibro-fatty and necrotic core vol-
umes remained unchanged with statin use; and on the
other hand, a significant fibrous plaque volume reduction
accompanied a significant increase in the dense calcium
volume. The data also suggests that there is a direct cor-
relation between statin intensity used in each study and
the effects on fibrous plaques and on dense calcium
volumes, despite the limited power of subgroup analysis.
Another very recent meta-analysis reached similar conclu-
sions using different analytical techniques [10].
An interesting aspect of plaque composition derived
from the study by Banach et al. is the role of coronary
calcification in the atherosclerotic process and its im-
plications on cardiovascular risk assessment. While
some authors propose that calcium formation is part of
the healing and stabilizing process of atherosclerosis,
other in vitro studies indicate that calcium location
may better explain the difference in plaque rupture risk
[11]. In fact, while clinical studies have firmly docu-
mented a direct association between the overall calcifi-
cation in coronary arteries (measured as either the
Agatston score or calcium volume) and cardiovascular
events, other studies suggest that the pattern and distri-
bution of calcium in coronary plaques may equally mat-
ter. A classical coronary computed tomography (CT)
angiography study by Motoyama et al. [12] indicated
that small “spotty” calcifications are associated with future
plaque ruptures, whereas a sub-analysis of the Multi-
Ethnic Study of Atherosclerosis (MESA) study [13] dem-
onstrated that calcium density is inversely associated with
events risk. These results, grounded by cellular and mo-
lecular data on the mechanisms regulating the pattern of
atherosclerotic calcification, suggest that smaller calcium
deposition (pro-inflammatory-driven microcalcifications)
are associated with plaque rupture and increased cardio-
vascular risk, while larger, denser calcium structures (anti-
inflammatory-driven macrocalcifications) are associated
with plaque stabilization and better outcomes, in agree-
ment with the increased dense calcification documented
with statin treatment [14].
Collectively, these results indicate that instead of regres-
sion, the use of statins can lead to plaque healing and
stabilization. The “healed” plaque is only discretely
smaller, although it has better structure and is less prone
to rupture. Even so, the occurrence of cardiovascular
events despite optimized treatment in a significant pro-
portion of patients receiving statins, the so-called “residual
risk”, suggests that the healing process is incomplete. In
fact, it has been proposed that statins and other preventive
measures alter the mechanisms leading to acute coronary
syndromes. Instead of plaque rupture, acute coronary syn-
dromes in those “healed” plaques are more likely to occur
by erosion. This change is thought to be related to the im-
proved plaque structure associated with the change in its
components.
Conclusions
In light of the evidence from the study by Banach et al.,
future clinical studies using invasive and non-invasive
techniques should move forward, with a deeper evalu-
ation of drug effects on atherosclerotic plaques. Instead
of absolute quantification of plaque and its components
(for example, plaque volume), we should focus on the
identification of plaque characteristics or changes in the
distribution of plaque components (for example, “spotty”
calcification, positive remodeling), as plaques are much
more likely to heal and stabilize than to regress.
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